Logo

Blueprint Medicines’s Ayvakyt Receives EC’s Approval for the Treatment of Adult Patients with Indolent Systemic Mastocytosis (ISM)

Share this
Blueprint Medicines

Blueprint Medicines’s Ayvakyt Receives EC’s Approval for the Treatment of Adult Patients with Indolent Systemic Mastocytosis (ISM)

Shots:

  • Blueprint Medicines has received approval from the EC for Ayvakyt (avapritinib) to treat adult patients with indolent systemic mastocytosis (ISM)
  • Following a positive opinion from the CHMP, the EC approved Ayvakyt based on data from the study (PIONEER) which demonstrated significant improvements compared to PBO in 1EP & 2EP, addressing overall symptoms & mast cell burden along with favorable safety profile
  • Ayvakyt, a kinase inhibitor designed to potently and selectively target KIT D816V that is already approved by EC for ISM, adults with ASM, SM-AHN/MCL/GIST

Ref: Blueprint Medicines | Image: Blueprint Medicines

Related News:- Blueprint Medicines Published (PIONEER) Trial Results of Ayvakit (avapritinib) for the Treatment of Indolent Systemic Mastocytosis in the NEJM

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions